Dental biofilms are formed in a multistep process that is initiated by the adhesion of oral bacteria to the dental hard surface. As dental biofilms are associated with oral diseases their control is necessary in order to maintain oral health. Recently, it was revealed that phytosphingosine (PHS)-treated hydroxyapatite discs showed anti-adhesive activity in a static in vitro biofilm model against Streptococcus mutans. The goal of the present study was to further unravel the anti-adhesive and anti-biofilm properties of PHS in both static and dynamic in vitro biofilm models against a full salivary inoculum. After 3 h under static conditions, bacterial adherence on PHS-treated cover glass slides was reduced by 60% compared to the untreated surface. After 6 and 24 h under static conditions, no significant differences in bacterial adherence were observed between PHS-treated and untreated cover glass slides. However, under dynamic conditions, i.e., the presence of shear forces, virtually no bacterial adherence was observed for up to 16 h on PHS-coated surfaces. Besides, PHS showed a strong bactericidal activity on salivary biofilms. Treatment of a 3- and 6-h statically grown biofilm resulted in a 99 and 94% reduction of viable cells, respectively, which was effectuated within minutes. In principle, these anti-adherence and anti-biofilm properties make PHS a promising candidate ingredient for use in oral care products aimed at oral microbial control.

Keywords:
Anti-adherence properties, Anti-biofilm properties, Phytosphingosine, Prevention, Saliva
1.
Arweiler NB, Netuschil L: The oral microbiota. Adv Exp Med Biol 2016;902:45-60.
2.
Belibasakis GN, Charalampakis G, Bostanci N, Stadlinger B: Peri-implant infections of oral biofilm etiology. Adv Exp Med Biol 2015;830:69-84.
3.
Bergsson G, Arnfinnsson J, Steingrimsson O, Thormar H: In vitro killing of candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother 2001a;45:3209-3212.
4.
Bergsson G, Arnfinnsson J, Steingrimsson O, Thormar H: Killing of gram-positive cocci by fatty acids and monoglycerides. APMIS 2001b;109:670-678.
5.
Busscher HJ, Norde W, van der Mei HC: Specific molecular recognition and nonspecific contributions to bacterial interaction forces. Appl Environ Microbiol 2008;74:2559-2564.
6.
Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322.
7.
Cukkemane N, Bikker FJ, Nazmi K, Brand HS, Sotres J, Lindh L, Arnebrant T, Veerman EC: Anti-adherence and bactericidal activity of sphingolipids against Streptococcus mutans. Eur J Oral Sci 2015;123:221-227.
8.
Donlan RM, Costerton JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-193.
9.
Eley BM: Antibacterial agents in the control of supragingival plaque - a review. Br Dent J 1999;186:286-296.
10.
Exterkate RA, Crielaard W, ten Cate JM: Different response to amine fluoride by Streptococcus mutans and polymicrobial biofilms in a novel high-throughput active attachment model. Caries Res 2010;44:372-379.
11.
Fey PD: Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections? Curr Opin Microbiol 2010;13:610-615.
12.
Fischer CL, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz PW: Antibacterial activity of sphingoid bases and fatty acids against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2012;56:1157-1161.
13.
Fischer CL, Walters KS, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz PW: Oral mucosal lipids are antibacterial against Porphyromonas gingivalis, induce ultrastructural damage, and alter bacterial lipid and protein compositions. Int J Oral Sci 2013;5:130-140.
14.
Frickenhaus S, Heinrich R: Kinetic and thermodynamic aspects of lipid translocation in biological membranes. Biophys J 1999;76:1293-1309.
15.
Galla HJ, Luisetti J: Lateral and transversal diffusion and phase transitions in erythrocyte membranes. An excimer fluorescence study. Biochim Biophys Acta 1980;596:108-117.
16.
Guan YH, Lath DL, Graaf T, Lilley TH, Brook AH: Moderation of oral bacterial adhesion on saliva-coated hydroxyapatite by polyaspartate. J Appl Microbiol 2003;94:456-461.
17.
Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O: Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35:322-332.
18.
Janus MM, Keijser BJ, Bikker FJ, Exterkate RA, Crielaard W, Krom BP: In vitro phenotypic differentiation towards commensal and pathogenic oral biofilms. Biofouling 2015;31:503-510.
19.
Keijser BJ, Zaura E, Huse SM, van der Vossen JM, Schuren FH, Montijn RC, ten Cate JM, Crielaard W: Pyrosequencing analysis of the oral microflora of healthy adults. J Dent Res 2008;87:1016-1020.
20.
Kolenbrander PE, Palmer RJ Jr, Periasamy S, Jakubovics NS: Oral multispecies biofilm development and the key role of cell-cell distance. Nat Rev Microbiol 2010;8:471-480.
21.
Krom BP, Willems HM: In vitro models for candida biofilm development. Methods Mol Biol 2016;1356:95-105.
22.
Martin M, Holscher T, Dragos A, Cooper VS, Kovacs AT: Laboratory evolution of microbial interactions in bacterial biofilms. J Bacteriol 2016;198:2564-2571.
23.
McBain AJ, Sissons C, Ledder RG, Sreenivasan PK, De Vizio W, Gilbert P: Development and characterization of a simple perfused oral microcosm. J Appl Microbiol 2005;98:624-634.
24.
Neilands J, Bikker FJ, Kinnby B: PAI-2/SerpinB2 inhibits proteolytic activity in a P. gingivalis-dominated multispecies bacterial consortium. Arch Oral Biol 2016;70:1-8.
25.
Ouarch M, Benhamou M, Chahid M, Kaidi H: Critical dynamics of lateral and transversal phase separations in bilayer biomembranes and surfactants. Eur Phys J E Soft Matter 2009;29:319-327.
26.
Payne DE, Boles BR: Emerging interactions between matrix components during biofilm development. Curr Genet 2016;62:137-141.
27.
Rautenbach M, Troskie AM, Vosloo JA: Antifungal peptides: to be or not to be membrane active. Biochimie 2016;130:132-145.
28.
Rosier BT, De Jager M, Zaura E, Krom BP: Historical and contemporary hypotheses on the development of oral diseases: are we there yet? Front Cell Infect Microbiol 2014;4:92.
29.
Snel M, Sleddering MA, Pijl H, Nieuwenhuizen WF, Frolich M, Havekes LM, Romijn JA, Jazet IM: The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome. Eur J Clin Nutr 2010;64:419-423.
30.
Sullan RM, Li JK, Crowley PJ, Brady LJ, Dufrene YF: Binding forces of Streptococcus mutans P1 adhesin. ACS Nano 2015;9:1448-1460.
31.
Tellefson LM, Germaine GR: Adherence of Streptococcus sanguis to hydroxyapatite coated with lysozyme and lysozyme-supplemented saliva. Infect Immun 1986;51:750-759.
32.
Valentijn-Benz M, van't Hof W, Bikker FJ, Nazmi K, Brand HS, Sotres J, Lindh L, Arnebrant T, Veerman EC: Sphingoid bases inhibit acid-induced demineralization of hydroxyapatite. Caries Res 2015;49:9-17.
33.
van Leeuwen PT, van der Peet JM, Bikker FJ, Hoogenkamp MA, Oliveira Paiva AM, Kostidis S, Mayboroda OA, Smits WK, Krom BP: Interspecies interactions between Clostridium difficile and Candida albicans. mSphere 2016;1:e00187-e00216.
34.
Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr: Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 1999;129:1239-1250.
35.
Volgenant CM, Hoogenkamp MA, Krom BP, Janus MM, ten Cate JM, de Soet JJ, Crielaard W, van der Veen MH: Red and green fluorescence from oral biofilms. PLoS One 2016;11:e0168428.
36.
Yonel N, Bikker FJ, Lagerweij MD, Kleverlaan CJ, van Loveren C, Ozen B, Cetiner S, van Strijp AJ: Anti-erosive effects of fluoride and phytosphingosine: an in vitro study. Eur J Oral Sci 2016;124:396-402.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.